Pharma Marketing News
PMN Home | Advertising Information | FAQs
About Us | Contact Us | Privacy Policy
Subscribe Glossary
Pharma Marketing Blog Pharmaguy Audio Podcasts Event Calendar PReader Surveys

Share |

Does the FDA Need to be Overhauled?
Results of a Pharma Marketing News Survey

FDA LogoThe Vioxx withdrawal put the Food and Drug Administration (FDA) under the spotlight. There were allegations that the FDA was in cahoots with Merck in keeping Vioxx problems under wraps (see, for example, "Will COX-2 Inhibitors Crash and Burn?"). A New York Times story reported that "Members of Congress, an internal F.D.A. whistleblower and prominent medical journals have said the agency is incapable of uncovering the perils of drugs that have been approved and are in wide distribution." ("At F.D.A., Strong Drug Ties and Less Monitoring," NYT, December 6, 2004).

Pharma Marketing News recently hosted a survey of pharmaceutical professionals, healthcare professionals, and the general public to get a better idea which reforms, if any, they would like to see implemented at FDA. The results are summarized in this article.

Read this article now. It's FREE...

Download PDF file

PMN42-05
Issue: Vol. 4, No. 2: February 2005
Word Count: 2131

Find other articles in related Topic Areas:

Vol 4, #2 Contents









Contact Information
Editor
Pharma Marketing News

Pharma Marketing News | Subscribe | Industry Insights | Podcasts | Pharmaguy | Blog
Surveys | Glossary | Conference Calendar | Advertising Information | FAQs | About Us | Privacy Policy

© 2014. Pharma Marketing Network. All rights reserved.